Akademiska Sjukhuset in Uppsala new strategic customer to Senzime
Press release: Uppsala, March 20, 2019. Senzime AB (publ) today announces that the Department of Neuroanesthesia at the University Hospital in Uppsala has signed an agreement to buy TetraGraph systems. The agreement is of a minor value and initially includes five TetraGraph systems and associated disposable sensors.
“In 2018, Senzime has begun the rollout of TetraGraph. The agreement with Akademiska is strategically important for us because it verifies and validates the need and our solutions also in the home market. ” Says Pia Renaudin, CEO of Senzime AB.
"We chose TetraGraph, based on EMG, because it is the only technology that does not require free access to the patient's hand. This type of monitoring is particularly important in neuroradiological intervention when the patients are anesthetized and receive a continuous infusion of muscle-blocking drugs throughout the procedure,” says Arne Wessén, senior physician at the Academic Hospital in Uppsala.
“We have begun an important commercial chapter in the company's history. At the same time, we have just started the journey towards achieving our ambition to become a world leader in patient monitoring, where the patient's needs is in focus. Allover the world, surgeons, anesthetists and healthcare professionals have demonstrated the need to improve how patients are followed up before, during and after surgery. We can now offer them smart, digital solutions for high quality follow-up and monitoring ”, comments Pia Renaudin, CEO of Senzime AB.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 (0)70-813 34 17, email: firstname.lastname@example.org
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, email@example.com, is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on March 20, 2019 15:30.